Announcing CSO Dr. David Milan
TO: Friends and contacts of the Fondation Leducq
We are very pleased to announce the appointment of Dr. David Milan as our Chief Scientific Officer at the Leducq organization effective January 2019.
An Assistant Professor of Medicine at Harvard Medical School, Dr. Milan has most recently had a teaching appointment at the Massachusetts General Hospital, where he has served on the faculty at the Cardiovascular Research Center and the Center for Human Genetic Research. His administrative positions included roles as Associate Director of the Cardiovascular Disease Fellowship Program and Associate Director of the Clinical Cardiac Electrophysiology Fellowship program.
Dr. Milan’s research has focused on three primary areas. First, his lab has elegantly been able to validate many of the genes associated with a broad range of cardiovascular traits and conditions including heart rate, mitral valve prolapse, atrial fibrillation, and fibromuscular dysplasia. Second, his laboratory has developed an innovative model of long QT syndrome in zebrafish. Using this screen, he was able to identify a class of compounds that rescues long QT syndrome and offers a new potential approach to treat the deadly arrhythmias associated with this condition. Finally, Dr. Milan has had a longstanding collaboration with Sue Slaugenhaupt and Robert Levine studying the genetics and developmental biology of mitral valve prolapse. Wonderfully, this collaboration first arose in the setting of a Ledcuq Foundation Transatlantic Network award and has continued on subsequent NIH RO1 awards.
Dr. Milan has received numerous honors and distinguished research grants in his field. We feel very fortunate such a talented basic scientist and clinician will be joining the Leducq organization.
We are looking forward to working with Dr. Milan to advance the Leducq mission.
David Tancredi, M.D., Ph.D.